Examining Ingredient Substitution in the Opioid Pharmaceutical Supply Chain: Findings from CDER’s Product Survey

F

FDA

Guest
Specifically, CDER’s Office of Compliance developed a multi-year opioid product quality survey designed to uncover impurities or substitutions of illegal, unsafe substances in place of the intended active pharmaceutical ingredient (API) in certain products. During this survey, FDA tested multiple


Baca selengkapnya di : http://www.fda.gov...
 
You must log in or register to reply here.
Top